Phathom Pharmaceuticals advertising spend, FY2025
Phathom Pharmaceuticals (PHAT) reported $61.3M of marketing and advertising expense for the fiscal year ended Dec 31, 2025. It does not tag advertising separately, so this broader figure stands in for it. That is 35.0% of revenue of $175M. Up 0.0% from FY2024.
Key facts
- Ad spend is 1.0x its FY2024 level ($61.3M), slower than revenue (3.2x).
- Phathom Pharmaceuticals's marketing and advertising expense is higher than the figure of 7% of the 458 US-listed companies tracked. Its ad-to-revenue ratio is 7.7x the median of 4.5%.
Ad spend by fiscal year
Ad spend as % of revenue
Ad spend in context, FY2025
Advertising was 21.9% of selling, general and administrative expense. Advertising was 1.9x research and development spending. The company reported an operating loss of $160M.
| Advertising | $61.3M | MarketingAndAdvertisingExpense |
|---|---|---|
| Selling, general and administrative | $280M | ad spend = 21.9% |
| Research and development | $32.8M | ad spend = 1.9x R&D |
| Operating loss | -$160M | |
| Net loss | -$221M |
Same fiscal year and filing as the ad spend. Selling and marketing and SG&A usually include advertising.
History
Download CSV| Fiscal year | Period end | Ad spend | YoY | Revenue | Ad / revenue | Tag | Filing |
|---|---|---|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | $61.3M | 0.0% | $175M | 35.0% | MarketingAndAdvertisingExpense | 10-K Feb 26, 2026 |
| FY2024 | Dec 31, 2024 | $61.3M | n/a | $55.3M | 110.9% | MarketingAndAdvertisingExpense | 10-K Feb 26, 2026 |
Ad spend, revenue and the ratio come from the linked filing. YoY compares each year with the fiscal year directly before it, under the same tag. A gap, a change of tag or a change of fiscal year end leaves it blank.
What the figure is
Marketing and advertising combined, as reported under the XBRL tag MarketingAndAdvertisingExpense. It is broader than advertising alone.
Compared with similar spenders
The 6 companies closest to Phathom Pharmaceuticals in latest-year ad spend.
| Rank | Company | Ad spend | Ad / revenue | YoY | Fiscal year |
|---|---|---|---|---|---|
| 420 | Boot Barn | $62.8M | 2.8% | +24.4% | FY2026 |
| 421 | Open Text | $62.3M | 1.2% | -3.9% | FY2026 |
| 422 | Illinois Tool Works | $62M | 0.4% | +6.9% | FY2025 |
| 423 | Phillips 66 | $62M | 0.05% | +21.6% | FY2025 |
| 424 | Simply Good Foods | $62M | 4.6% | -18.5% | FY2026 |
| 425 | Phathom Pharmaceuticals | $61.3M | 35.0% | 0.0% | FY2025 |
| 426 | Trex | $61M | 5.2% | +14.0% | FY2025 |
Full ranking of 458 companies · Highest ad-to-revenue #14 · More on ads than R&D #66 · Ads above operating profit #148
Questions
How much does Phathom Pharmaceuticals spend on advertising?
Phathom Pharmaceuticals does not report advertising separately. Its marketing and advertising expense was $61.3M in fiscal 2025, the year ended Dec 31, 2025, according to its 10-K filed Feb 26, 2026. That figure is broader than advertising.
What percentage of revenue does Phathom Pharmaceuticals spend on advertising?
35.0% of revenue in fiscal 2025 ($61.3M of marketing and advertising expense against $175M). The median across the 458 companies tracked is 4.5%.
Is Phathom Pharmaceuticals spending more on advertising?
Yes. Ad spend rose 0.0% in fiscal 2025 from fiscal 2024.
How does Phathom Pharmaceuticals rank by advertising spend?
#425 of 458 US-listed companies with $50M or more in ad spend, ranked on each company's latest fiscal year.
Does Phathom Pharmaceuticals spend more on advertising than on R&D?
Yes. In fiscal 2025 it spent $61.3M on advertising and $32.8M on research and development.
What does Phathom Pharmaceuticals's advertising figure include?
Marketing and advertising combined, as reported under the XBRL tag MarketingAndAdvertisingExpense. It is broader than advertising alone.
Company and source
- Filing
- 10-K for FY2025, filed Feb 26, 2026
- Accession number
0001193125-26-073379- Company
- Phathom Pharmaceuticals, Inc., CIK 1783183, SIC 2834 (Pharmaceutical Preparations)
- Headquarters
- Florham Park, NJ
- Incorporated in
- DE
- Fiscal year ends
- December 31
- Listed on
- Nasdaq
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- Data
- SEC EDGAR XBRL company facts, retrieved Nov 18, 2026. Methodology.
- Cite
- Phathom Pharmaceuticals advertising spend, FY2024-FY2025. Aleksei Trudov, io.trudov.com, from SEC EDGAR XBRL company facts (latest: 10-K filed Feb 26, 2026), retrieved Nov 18, 2026. https://io.trudov.com/company/phathom-pharmaceuticals/advertising-spend/
- Download
- CSV, all years · CSV, all 458 companies